home / stock / algs / algs news

ALGS News and Press, Aligos Therapeutics Inc. From 05/04/23

Stock Information
Company Name: Aligos Therapeutics Inc.
Stock Symbol: ALGS
Market: NASDAQ
Website: aligos.com
Menu
ALGS ALGS Quote ALGS Short ALGS News ALGS Articles ALGS Message Board
Get ALGS Alerts

News, Short Squeeze, Breakout and More Instantly...
ALGS - Aligos Therapeutics GAAP EPS of -$0.53 misses by $0.05, revenue of $2.58M

2023-05-04 17:25:18 ET Aligos Therapeutics press release ( NASDAQ: ALGS ): Q1 GAAP EPS of -$0.53 misses by $0.05 . Revenue of $2.58M (+0.4% Y/Y). Cash, cash equivalents and investments totaled $103.5 million as of March 31, 2023, compared with $125.8 million as o...
ALGS - Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and finan...

ALGS - Aligos Therapeutics to Announce First Quarter Results on May 4, 2023

SOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral dise...

ALGS - Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023

SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present s...
ALGS - Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference

SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company presented Phas...

ALGS - Aligos Therapeutics GAAP EPS of -$0.51 misses by $0.02, revenue of $3.54M beats by $1.39M

2023-03-09 16:46:36 ET Aligos Therapeutics press release ( NASDAQ: ALGS ): Q4 GAAP EPS of -$0.51 misses by $0.02 . Revenue of $3.54M (+856.8% Y/Y) beats by $1.39M . Cash, cash equivalents and investments totaled $125.8 million as of December 31, 2022, compared ...

ALGS - Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and fin...
ALGS - Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in nonalcoholic steatohe...

ALGS - Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company is delivering se...

ALGS - Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company will deliver sev...
Previous 10 Next 10